Patents by Inventor David Michael Remick

David Michael Remick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR
    Publication number: 20250042899
    Abstract: The present invention relates to the synthesis of 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo [4,3-c] pyridine-5-carbonyl] indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a salt thereof, and related synthetic intermediate compounds.
    Type: Application
    Filed: September 3, 2024
    Publication date: February 6, 2025
    Inventors: Ayman D. ALLIAN, Kenneth Derek BERGLUND, Kevin Paul COLE, Ashlee Jeanette DAVIS, Molly HESS, Adriana JEMISON, Mark Steven KERR, Audrey Grace MACK, Xavier A. ORTIZ-MEDINA, David Michael REMICK, Derek Robert STARKEY, Radhe Krishan VAID, Qiang YANG
  • Treprostinil salt
    Patent number: 12102610
    Abstract: A novel salt of treprostinil and methods of its preparation and use are disclosed.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: October 1, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventor: David Michael Remick
  • METHODS FOR THE PREPARATION AND DOSE REGIMENS FOR USE OF SSTR4 AGONISTS AND SALTS THEREOF
    Publication number: 20240307349
    Abstract: Method for preparing SSTR4 agonist compounds. Method for preparing SSTR4 agonist compounds through a diasteromerically selective cyclization reaction without the need for a separate epimerization step. Novel intermediates for preparing SSTR4 agonist compounds. Dose regimens for the treatment of pain and/or neuropathic pain, such as diabetic peripheral neuropathy, central neuropathy, or mixed neuropathy.
    Type: Application
    Filed: March 6, 2024
    Publication date: September 19, 2024
    Inventors: William Brian KIELBASA, Scott Alan MONK, Eric Michael PEARLMAN, David Michael REMICK, John Robert RIZZO
  • POLYMORPHS OF AN SSAO INHIBITOR
    Publication number: 20240308975
    Abstract: Provided herein are polymorphs of (2E)-3-fluoro-2-({[2-(4-methoxypiperidin-1-yl)pyrimidin-5 -yl]oxy} methyl)prop-2-en-1-aminium 4-methylbenzenesulfonate, compositions thereof, methods of preparation thereof, and methods of use thereof.
    Type: Application
    Filed: May 28, 2024
    Publication date: September 19, 2024
    Inventor: David Michael REMICK
  • PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20240199629
    Abstract: Disclosed are methods of making selective estrogen receptor degraders (SERDs) of Formula A, as well as intermediates thereof, salts thereof including a pharmaceutically acceptable salt, and pharmaceutical compositions thereof: wherein either R1 or R2 is independently Cl, F, —CF3, or —CH3, and the other is H; and R7 is H or PG.
    Type: Application
    Filed: January 31, 2024
    Publication date: June 20, 2024
    Inventors: Alonso Jose ARGUELLES DELGADO, Boris Arnoldovich CZESKIS, Mai Khanh Nguyen HAWK, Douglas Patton KJELL, Yu LU, Nicholas Andrew MAGNUS, David Michael REMICK
  • Processes for the preparation of selective estrogen receptor degraders
    Patent number: 11926634
    Abstract: Disclosed are methods of making selective estrogen receptor degraders (SERDs) of Formula A, as well as intermediates thereof, salts thereof including a pharmaceutically acceptable salt, and pharmaceutical compositions thereof: wherein either R1 or R2 is independently Cl, F, —CF3, or —CH3, and the other is H; and R7 is H or PG.
    Type: Grant
    Filed: January 27, 2023
    Date of Patent: March 12, 2024
    Assignee: Eli Lilly and Company
    Inventors: Alonso Jose Arguelles Delgado, Boris Arnoldovich Czeskis, Mai Khanh Nguyen Hawk, Douglas Patton Kjell, Yu Lu, Nicholas Andrew Magnus, David Michael Remick
  • SSTR4 AGONIST SALTS
    Publication number: 20240067628
    Abstract: The present invention relates to specific salts of (1S,5R)-(1?,5?,6?)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.
    Type: Application
    Filed: August 7, 2023
    Publication date: February 29, 2024
    Inventors: David Andrew COATES, David Michael REMICK
  • SSTR4 agonist salts
    Patent number: 11834435
    Abstract: The present invention relates to specific salts of (1S,5R)-(1?,5?,6?)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.
    Type: Grant
    Filed: September 14, 2022
    Date of Patent: December 5, 2023
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, David Michael Remick
  • Polymorphs of an SSAO inhibitor
    Patent number: 11820754
    Abstract: Provided herein are polymorphs of (2E)-3-fluoro-2-({[2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl]oxy}methyl)prop-2-en-1-aminium 4-methylbenzenesulfonate, compositions thereof, methods of preparation thereof, and methods of use thereof.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: November 21, 2023
    Assignee: Eli Lilly and Company
    Inventor: David Michael Remick
  • PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20230242545
    Abstract: Disclosed are methods of making selective estrogen receptor degraders (SERDs) of Formula A, as well as intermediates thereof, salts thereof including a pharmaceutically acceptable salt, and pharmaceutical compositions thereof: wherein either R1 or R2 is independently Cl, F, —CF3, or —CH3, and the other is H; and R7 is H or PG.
    Type: Application
    Filed: January 27, 2023
    Publication date: August 3, 2023
    Inventors: Alonso Jose ARGUELLES DELGADO, Boris Arnoldovich CZESKIS, Mai Khanh Nguyen HAWK, Douglas Patton KJELL, Yu LU, Nicholas Andrew MAGNUS, David Michael REMICK
  • SSTR4 AGONIST SALTS
    Publication number: 20230099116
    Abstract: The present invention relates to specific salts of (1S,5R)-(1?,5?,6?)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.
    Type: Application
    Filed: September 14, 2022
    Publication date: March 30, 2023
    Inventors: David Andrew COATES, David Michael REMICK
  • CRYSTALLINE FORMS OF A CD73 INHIBITOR
    Publication number: 20220289716
    Abstract: The present invention relates to crystalline forms of 5-[5-[2-isopropylcyclopropyl]-6-methyl-pyridazin-3-yl]-1H-pyrimidine-2,4-dione, and pharmaceutical compositions comprising them, which inhibit the activity of CD73 and are useful for treating cancer.
    Type: Application
    Filed: August 24, 2020
    Publication date: September 15, 2022
    Inventors: Susana Maria GARCIA-CERRADA, Yu LU, David Michael REMICK
  • SALTS OF 5,6-DIHYDRO-4H-THIENO[2,3-C]PYRROL-4-ONE COMPOUND AS ERK INHIBITORS
    Publication number: 20220153750
    Abstract: The present invention provides novel crystalline salt forms of 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one.
    Type: Application
    Filed: March 19, 2020
    Publication date: May 19, 2022
    Inventors: David Andrew COATES, Sajan JOSEPH, Mark Andrew POLIZZI, David Michael REMICK
  • POLYMORPHS OF AN SSAO INHIBITOR
    Publication number: 20220089563
    Abstract: Provided herein are polymorphs of (2E)-3-fluoro-2-({[2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl]oxy}methyl)prop-2-en-1-aminium 4-methylbenzenesulfonate, compositions thereof, methods of preparation thereof, and methods of use thereof.
    Type: Application
    Filed: August 24, 2021
    Publication date: March 24, 2022
    Inventor: David Michael REMICK
  • Novel Treprostinil Salt
    Publication number: 20220047535
    Abstract: A novel salt of treprostinil and methods of its preparation and use are disclosed.
    Type: Application
    Filed: September 11, 2019
    Publication date: February 17, 2022
    Inventor: David Michael Remick
  • (E)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PYRROLIDIN-3-YL 4-((3-ISOPROPYL-5-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)AMINO)PIPERIDINE-1-CARBOXYLATE FOR INHIBITING CDK7
    Publication number: 20210032257
    Abstract: The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 22, 2020
    Publication date: February 4, 2021
    Inventors: David Andrew COATES, Carlos MONTERO, Bharvin Kumar Rameschandra PATEL, David Michael REMICK, Vipin YADAV
  • (E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7
    Patent number: 10787460
    Abstract: The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: September 29, 2020
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Carlos Montero, Bharvin Kumar Rameschandra Patel, David Michael Remick, Yipin Yadav
  • (E)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PYRROLIDIN-3-YL 4-((3-ISOPROPYL-5-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)AMINO)PIPERIDINE-1-CARBOXYLATE FOR INHIBITING CDK7
    Publication number: 20200017513
    Abstract: The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 26, 2019
    Publication date: January 16, 2020
    Inventors: David Andrew COATES, Carlos MONTERO, Bharvin Kumar Rameschandra PATEL, David Michael REMICK, Yipin YADAV
  • COMPOUNDS USEFUL FOR INHIBITING CDK7
    Publication number: 20190144456
    Abstract: The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 16, 2019
    Inventors: David Andrew Coates, Carlos Montero, Bharvin Kumar Rameschandra Patel, David Michael Remick, Vipin Yadav
  • Selective BACE1 inhibitors
    Patent number: 10011610
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: July 3, 2018
    Assignee: Eli Lilly and Company
    Inventors: David Michael Remick, Simon James Richards, Adam Jan Sanderson